Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (avastin) for treatment of CNV associated with AMD

Retina

Volumn 29, Issue 3, 2009, Pages 319-324

  Modarres, Mehdi ^a   Naseripour, Masood ^a   Falavarjani, Khalil Ghasemi ^a,b   Nikeghbali, Aminollah ^a   Hashemi, Masih ^a   Parvaresh, Mohammad Mehdi ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; BEVACIZUMAB; PREDNISOLONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EYE EXAMINATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA FOVEA; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; THICKNESS; VISUAL ACUITY; VITREOUS BODY DETACHMENT; VITREOUS DISEASE; VITRITIS;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; PROSPECTIVE STUDIES; RETINA; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 67749127444     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318198148e     Document Type: Article

References (31)

1. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004; 137:486-495.
2. Age-Related Eye Disease Study Research Group. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol 2003;121: 1621-1624.
3. Eye Diseases Prevalence Research Group. Prevalence of age related macular degeneration in the United States. Arch Ophthalmol 2004;122:564 -572.
4. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-1642.
5. Amin R, Puklin JE, Frank RN. Growth factor localization in choroidal neovascular membrane of age-related macular degeneration. Invest Ophthalmol Vis Sci 1994;35:3178-3188.
6. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997;81:154-162.
7. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113:363-372.
8. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-390.
9. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:1-9.
10. Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:246-252.
11. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration. A phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;113:633.
12. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature 2004;3:391-400.
13. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599.
14. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
15. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporphin for neovascular age-related macular degeneration. N Engl J Med 2006;335:1432-1444.
16. Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 2006;26:994-998.
17. Freeman WR, Falkenstein I. Avastin and new treatments for AMD: where are we? Retina 2006;26:853-858.
18. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335.
19. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr, Scott IU. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 doseescalation study. Invest Ophthalmol Vis Sci 2006;47:4569-4578.
20. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007;114: 743-750.
21. Hernández-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, et al. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 2007;27:707-712.
22. Wu L, Arevalo JF, Roca JA, et al. Comparison of two doses intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina 2008;28:212-219.
23. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-859.
24. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005;112: 1048-1053.
25. Rosenfeld PJ, Heier JS, Hantsbarger G, et al. Tolerability and efficacy of multiple escalating doses of Ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 2006;113:623-632.
26. Bakri SJ, Larson TA, Edwards AO. Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol 2008;246:779-781.
27. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006; 26:257-261.
28. Feiner L, Barr EE, Shui YB, Holekamp NM, Brantley MA Jr. Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina 2006;26:882-888.
29. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006;26:262-269.
30. Fung AE, Rosenfeld PJ, Reichel E. The International Intrav-itreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349.
31. Chieh JJ, Fekrat S. Large subretinal hemorrhage after intrav-itreal bevacizumab (Avastin) for age-related macular degeneration. Ann Ophthalmol (Skokie) 2007;39:51-52.